Literature DB >> 7030750

Correlation between propranolol in plasma and urine, renin-aldosterone system and blood pressure in essential hypertension.

E B Pedersen, H J Kornerup, O L Pedersen, F Andreasen, P Bjerregaard.   

Abstract

Thirty patients with mild or moderate essential hypertension, and a fixed elevation of diastolic blood pressure, were randomly allocated to three groups and treated with propranolol 40 mg x 4 (Group 1), 80 mg x 4 (group 2) and 160 mg x 4 (Group 3). Blood pressure (BP), pulse rate (PR), plasma renin activity (PRA), plasma aldosterone concentration (PAC), total plasma propranolol (tPP), free plasma propranolol (fPP), and 24 h urinary propranolol excretion (UP) were determined at the end of four consecutive periods: (A) after four weeks without any treatment; (B) after two to three weeks during which the propranolol dose was gradually increased to the intended level; (C) after four weeks, and (D) after eight weeks of unchanged treatment. The maximum reduction in diastolic BP occurred after period B, and in systolic BP after Period C, for Groups 2 and 3, and for all groups together; for Group 1, however, the maximum diastolic BP reduction was first seen after period C. PR was reduced to the same level in all groups after period B. After period B, PRA an PAC fell in all groups, and remained reduced during C and D Group 1. After periods C and D, PRA and PAC in Groups 2 and 3 did not differ significantly from the levels after period A; tPP, fPP and UP were significantly correlated with the propranolol dose, and were lowest in Group 1 and highest in Group 3; UP was negatively correlated with systolic but not diastolic BP in Periods B, C and D. In contrast neither fPP nor tPP were correlated with systolic or diastolic BP. There was no significant correlation between PRA, PAC and changes in PRA or PAC on the one hand and tPP, fPP, UP, BP or changes in BP on the other. It was concluded that propranolol effectively reduced BP, but diastolic BP reduction was most rapidly obtained at 320 and 640 mg daily, that the activity of the renin -aldosterone system was initially suppressed in all group, but for unknown reasons it increased towards the control level after seven to eleven weeks of therapy with 320 and 640 mg/day, and that the reduction in systolic BP increased with higher doses of propranolol and with increasing urinary propranolol excretion.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7030750     DOI: 10.1007/bf00618774

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  Relationship between plasma aldosterone concentration and plasma potassium in patients with essential hypertension during alprenolol treatment.

Authors:  E B Pedersen; H J Kornerup
Journal:  Acta Med Scand       Date:  1976

2.  Effect of sotalol on haemodynamics and renin-angiotensin-aldosterone system in hypertensive patients.

Authors:  A Verniory; M Staroukine; F Delwiche; M Telerman
Journal:  Clin Sci Mol Med       Date:  1976-07

3.  Plasma renin concentration measured by use of radioimmunoassay for angiotensin I.

Authors:  J Giese; M Jörgensen; M D Nielsen; J O Lund; O Munck
Journal:  Scand J Clin Lab Invest       Date:  1970-12       Impact factor: 1.713

4.  Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension.

Authors:  H Ibsen; P Sederberg-Olsen
Journal:  Clin Sci       Date:  1973-02       Impact factor: 6.124

5.  Relation of propranolol plasma level to beta-blockade during oral therapy.

Authors:  R Zacest; J Koch-Weser
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

Review 6.  Some aspects of kidney function, the renin-aldosterone system and sympathetic activity in essential hypertension.

Authors:  E B Pedersen
Journal:  Acta Med Scand Suppl       Date:  1980

7.  Plasma concentrations of propranolol in patients with essential hypertension.

Authors:  A Lehtonen; J Kanto; T Kleimola
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

8.  Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension.

Authors:  J W Hollifield; K Sherman; R V Zwagg; D G Shand
Journal:  N Engl J Med       Date:  1976-07-08       Impact factor: 91.245

Review 9.  Beta-adrenoreceptor blockade in hypertension.

Authors:  A R Lorimer; F G Dunn; J V Jones; T D Lawrie
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

10.  Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.

Authors:  L Wong; R L Nation; W L Chiou; P K Mehta
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

View more
  2 in total

Review 1.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

2.  Changes in blood chemistry in hypertensive patients during propranolol therapy.

Authors:  F Andreasen; P Jakobsen; H J Kornerup; E B Pedersen; O L Pedersen; J Weeke
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.